Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 34 citing articles:

Chitosan Nanoparticle Encapsulation of Antibacterial Essential Oils
Arvind Negi, Kavindra Kumar Kesari
Micromachines (2022) Vol. 13, Iss. 8, pp. 1265-1265
Open Access | Times Cited: 60
Optimization of PROTAC Ternary Complex Using DNA Encoded Library Approach
Qiuxia Chen, Chuan Liu, Wei Wang, et al.
ACS Chemical Biology (2023) Vol. 18, Iss. 1, pp. 25-33
Open Access | Times Cited: 28
PROTACs: Novel tools for improving immunotherapy in cancer
Shizhe Li, Ting Chen, Jinxin Liu, et al.
Cancer Letters (2023) Vol. 560, pp. 216128-216128
Closed Access | Times Cited: 25
PROTACs: A novel strategy for cancer drug discovery and development
Xin Han, Yi Sun
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 24
Development of antibody‐drug conjugates in cancer: Overview and prospects
Dan‐Yun Ruan, Hao‐Xiang Wu, Qi Meng, et al.
Cancer Communications (2023) Vol. 44, Iss. 1, pp. 3-22
Open Access | Times Cited: 23
Antibody-drug conjugates for targeted cancer therapy: recent advances in potential payloads
Meiyang Xi, Jingjing Zhu, Fengxia Zhang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 276, pp. 116709-116709
Closed Access | Times Cited: 8
PROTAC-Mediated Dual Degradation of BCL-xL and BCL-2 Is a Highly Effective Therapeutic Strategy in Small-Cell Lung Cancer
Sajid Khan, Lin Cao, J Wiegand, et al.
Cells (2024) Vol. 13, Iss. 6, pp. 528-528
Open Access | Times Cited: 5
Acute myeloid leukemia resistant to venetoclax-based therapy: What does the future hold?
Prajwal Dhakal, Melissa L. Bates, Michael H. Tomasson, et al.
Blood Reviews (2022) Vol. 59, pp. 101036-101036
Closed Access | Times Cited: 26
PROTAC: targeted drug strategy. Principles and limitations
O. A. Koroleva, Yu. V. Dutikova, A.V. Trubnikov, et al.
Russian Chemical Bulletin (2022) Vol. 71, Iss. 11, pp. 2310-2334
Open Access | Times Cited: 22
Novel formats of antibody conjugates: recent advances in payload diversity, conjugation, and linker chemistry
Tomohiro Fujii, Yutaka Matsuda
Expert Opinion on Biological Therapy (2023) Vol. 23, Iss. 11, pp. 1053-1065
Closed Access | Times Cited: 12
Anti‐apoptotic protein BCL‐XL as a therapeutic vulnerability in gastric cancer
Yumin Wei, Ping Zhang, Chao Wang, et al.
Animal Models and Experimental Medicine (2023) Vol. 6, Iss. 3, pp. 245-254
Open Access | Times Cited: 10
Insights into targeting cellular senescence with senolytic therapy: The journey from preclinical trials to clinical practice
Peng Chen, Yulai Wang, Benhong Zhou
Mechanisms of Ageing and Development (2024) Vol. 218, pp. 111918-111918
Closed Access | Times Cited: 3
Tipping the balance: toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma
Yvonne J. Thus, Eric Eldering, Arnon P. Kater, et al.
Leukemia (2022) Vol. 36, Iss. 9, pp. 2165-2176
Open Access | Times Cited: 16
Bcl-xL targeting eliminates ageing tumor-promoting neutrophils and inhibits lung tumor growth
Anita Bodac, Abdullah Mayet, Sarika Rana, et al.
EMBO Molecular Medicine (2023) Vol. 16, Iss. 1, pp. 158-184
Open Access | Times Cited: 9
Indene-Derived Hydrazides Targeting Acetylcholinesterase Enzyme in Alzheimer’s: Design, Synthesis, and Biological Evaluation
Shraddha Manish Gupta, Ashok Behera, Neetesh Kumar Jain, et al.
Pharmaceutics (2022) Vol. 15, Iss. 1, pp. 94-94
Open Access | Times Cited: 15
Protein isoform-centric therapeutics: expanding targets and increasing specificity
Peter Kjer-Hansen, Tri Giang Phan, Robert J. Weatheritt
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 10, pp. 759-779
Closed Access | Times Cited: 2
Proteolysis Targeting Chimeric Molecules: Tuning Molecular Strategies for a Clinically Sound Listening
Federica Pedrucci, Claudia Pappalardo, Giovanni Marzaro, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 12, pp. 6630-6630
Open Access | Times Cited: 13
Azobenzene Photoswitches in Proteolysis Targeting Chimeras: Photochemical Control Strategies and Therapeutic Benefits
Arvind Negi, Charline Kieffer, Anne Sophie Voisin‐Chiret
ChemistrySelect (2022) Vol. 7, Iss. 23
Open Access | Times Cited: 12
Estrogen Receptor-α Targeting: PROTACs, SNIPERs, Peptide-PROTACs, Antibody Conjugated PROTACs and SNIPERs
Arvind Negi, Kavindra Kumar Kesari, Anne Sophie Voisin‐Chiret
Pharmaceutics (2022) Vol. 14, Iss. 11, pp. 2523-2523
Open Access | Times Cited: 12
Light-Activating PROTACs in Cancer: Chemical Design, Challenges, and Applications
Arvind Negi, Kavindra Kumar Kesari, Anne Sophie Voisin‐Chiret
Applied Sciences (2022) Vol. 12, Iss. 19, pp. 9674-9674
Open Access | Times Cited: 10
From the divergence of senescent cell fates to mechanisms and selectivity of senolytic drugs
Valentin L’Hôte, Carl Mann, Jean‐Yves Thuret
Open Biology (2022) Vol. 12, Iss. 9
Open Access | Times Cited: 9
PROTAC-mediated dual degradation of BCL-xL and BCL-2 is a highly effective therapeutic strategy in small-cell lung cancer
Sajid Khan, Lin Cao, J Wiegand, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Precision oncology revolution: CRISPR-Cas9 and PROTAC technologies unleashed
Karim Kanbar, Roy El Darzi, Diana E. Jaalouk
Frontiers in Genetics (2024) Vol. 15
Open Access | Times Cited: 1
MicroRNAs-Based Theranostics against Anesthetic-Induced Neurotoxicity
R. Walker Minz, Praveen Sharma, Arvind Negi, et al.
Pharmaceutics (2023) Vol. 15, Iss. 7, pp. 1833-1833
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top